if a copied ReCell only needs an 510k approval then the costs are very moderate for any large pharma. But I don't know if it's only a 510k approval required.
PNV's BTM is a good example.
Patent extension, page-40
Add AVH (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$2.45 |
Change
-0.020(0.81%) |
Mkt cap ! $166.8M | |||
| Open | High | Low | Value | Volume |
| $2.47 | $2.49 | $2.44 | $130.6K | 52.93K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 33235 | $2.45 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $2.46 | 20078 | 5 |
View Market Depth
| Last trade - 11.26am 11/07/2024 (20 minute delay) ? |
| AVH (ASX) Chart |